Advertisement


Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy

ASH 2025

Advertisement

Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicinbased therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) (Abstract 441). 



Related Videos

Multiple Myeloma

Benjamin Diamond, MD, on a Novel Quadruplet for Relapsed/Refractory Multiple Myeloma

Benjamin Diamond, MD, of the University of Miami, describes findings from the single-center phase II REKINDLE trial, which looked at the combination regimen of iberdomide, carfilzomib, daratumumab, and dexamethasone in patients with early relapsed/refractory multiple myeloma (Abstract 251). 

Leukemia

Jayastu Senapati, MBBS, on B-Cell ALL: Brexucabtagene Autoleucel as Consolidation Therapy

Jayastu Senapati, MBBS, of The University of Texas MD Anderson Cancer Center, presents initial results from a phase II trial of brexucabtagene autoleucel as consolidation therapy in front-line high-risk B-cell acute lymphoblastic leukemia (B-ALL) or relapsed/refractory B-ALL after cytoreduction (Abstract 1573). 

Myelodysplastic Syndromes

Amer Zeidan, MBBS, on TP53-Mutated Higher-Risk MDS: Bexmarilimab Plus Azacitidine

Amer Zeidan, MBBS, of Yale School of Medicine, shares results from the phase I/II BEXMAB study, which examined the safety, tolerability and preliminary efficacy of bexmarilimab—a novel macrophage checkpoint inhibitor targeting Clever-1—in combination with the standard of care, azacitidine, in patients with higher-risk myelodysplastic syndromes (MDS), including those with TP53-mutated disease. (Abstract 236).

Leukemia

Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy

Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)and could challenge the current treatment standard (Abstract 6). 

Multiple Myeloma

Shahzad Raza, MD, on Relapsed/Refractory Multiple Myeloma: Novel Doublet in Patients With Extramedullary Disease

Shahzad Raza, MD, of Cleveland Clinic, presents updated phase II results of the RedirecTT-1 trial, focusing on the efficacy and safety of talquetamab combined with teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease (Abstract 698). The study also received simultaneous publication in The New England Journal of Medicine.

Advertisement

Advertisement




Advertisement